JP2023542295A5 - - Google Patents

Info

Publication number
JP2023542295A5
JP2023542295A5 JP2023516467A JP2023516467A JP2023542295A5 JP 2023542295 A5 JP2023542295 A5 JP 2023542295A5 JP 2023516467 A JP2023516467 A JP 2023516467A JP 2023516467 A JP2023516467 A JP 2023516467A JP 2023542295 A5 JP2023542295 A5 JP 2023542295A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
linker
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050337 external-priority patent/WO2022056494A1/en
Publication of JP2023542295A publication Critical patent/JP2023542295A/ja
Publication of JP2023542295A5 publication Critical patent/JP2023542295A5/ja
Pending legal-status Critical Current

Links

JP2023516467A 2020-09-14 2021-09-14 Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用 Pending JP2023542295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077983P 2020-09-14 2020-09-14
US63/077,983 2020-09-14
PCT/US2021/050337 WO2022056494A1 (en) 2020-09-14 2021-09-14 Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof

Publications (2)

Publication Number Publication Date
JP2023542295A JP2023542295A (ja) 2023-10-06
JP2023542295A5 true JP2023542295A5 (https=) 2024-09-20

Family

ID=78080567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516467A Pending JP2023542295A (ja) 2020-09-14 2021-09-14 Glp1ペプチド模倣薬を含む抗体薬物複合体及びその使用

Country Status (12)

Country Link
US (2) US12280124B2 (https=)
EP (1) EP4210767A1 (https=)
JP (1) JP2023542295A (https=)
KR (1) KR20230070337A (https=)
CN (1) CN116615251A (https=)
AU (1) AU2021339892A1 (https=)
CA (1) CA3191304A1 (https=)
CL (2) CL2023000678A1 (https=)
CO (1) CO2023004558A2 (https=)
IL (1) IL301074A (https=)
MX (1) MX2023002974A (https=)
WO (1) WO2022056494A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3191304A1 (en) 2020-09-14 2022-03-17 Amy Han Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
JP2025512735A (ja) 2022-03-11 2025-04-22 リジェネロン ファーマシューティカルズ,インク. Glp1ペプチド模倣体を含む抗glp1r抗体係留型薬物コンジュゲートおよびその使用
WO2024027715A1 (en) * 2022-08-01 2024-02-08 Sciwind Biosciences Usa Co., Ltd Anti-glp-1r antibodies and uses thereof
AU2024229138A1 (en) 2023-02-27 2025-09-18 Regeneron Pharmaceuticals, Inc. Liquid phase peptide support synthesis of peptides and peptidomimetics
US20250171516A1 (en) 2023-11-03 2025-05-29 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
TW202535467A (zh) * 2023-12-29 2025-09-16 大陸商江蘇恆瑞醫藥股份有限公司 抗體-多肽偶聯物及其醫藥用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
FR2937972B1 (fr) 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011048614A2 (en) * 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
US9911931B2 (en) 2014-06-26 2018-03-06 Universal Display Corporation Organic electroluminescent materials and devices
GB2551945B (en) * 2015-12-18 2021-09-08 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
IL313587A (en) * 2017-01-17 2024-08-01 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
JP7702428B2 (ja) 2020-05-12 2025-07-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗glp1rアンタゴニスト抗体およびその使用方法
CA3191304A1 (en) 2020-09-14 2022-03-17 Amy Han Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof

Similar Documents

Publication Publication Date Title
JP2023542295A5 (https=)
JP2021113191A5 (https=)
DK2678037T3 (en) Branched linker for protein pharmaceutical conjugates
CN117980327A (zh) 抗体的特异性偶联
JP4833857B2 (ja) ポリマー残基を生物活性部分に結合するための分岐した分子骨格
CA2991975C (en) Novel linkers and their uses in specific conjugation of drugs to a biological molecule
JP2023524271A5 (https=)
JP2015526434A5 (https=)
JPWO2019240288A1 (ja) 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
JP2007526330A5 (https=)
JP2023129495A5 (https=)
RU2010149608A (ru) Антиангиогенные соединения
JP2022541517A5 (https=)
RU2016130121A (ru) Конъюгаты связующего (ADC) с ингибиторами KSP
JP2019536772A (ja) 共役連結体、該連結体を含有する細胞結合分子−薬物共役体、並びに該共役体及び連結体の使用及び製造方法
CN102333788A (zh) 因子viii的修饰
JP2021513990A5 (https=)
JP6230199B2 (ja) 標的化送達のための、小分子インテグリンアンタゴニストに共有結合により連結されたキトサン
JP2022553702A5 (https=)
JP2024524613A5 (https=)
JP2025512735A5 (https=)
JP2022554094A5 (https=)
JP2023538524A5 (https=)
JP2008504237A5 (https=)
JP2026041725A (ja) 新規な連結体及び生体分子と薬物との特異的共役におけるその使用